Feature Channels: Pharmaceuticals

Filters close
Newswise: Beta blocker used to treat heart problems and other medical concerns could be new treatment for sickle cell cardiomyopathy
Released: 4-Jan-2024 7:05 AM EST
Beta blocker used to treat heart problems and other medical concerns could be new treatment for sickle cell cardiomyopathy
Indiana University

A beta blocker typically used to treat heart problems, hemangioma, migraines and anxiety could be a new therapeutic for patients with sickle cell disease.

Released: 3-Jan-2024 5:05 PM EST
Study demonstrates potency of synthetic antibiotic against serious chronic infections
University of Liverpool

A new synthetic antibiotic developed by University of Liverpool researchers is shown to be more effective than established drugs against ‘superbugs’ such as MRSA, a new study shows.

Released: 3-Jan-2024 2:05 PM EST
Inhaled statins show promise as effective asthma treatment
UC Davis Health

In an NIH-funded study, UC Davis pulmonology researchers are exploring whether delivering statins by inhalation can lead to better outcomes for people with asthma.

Released: 3-Jan-2024 12:00 PM EST
Molecular Diagnostics Research That Could Transform Healthcare Featured in the January Issue of ADLM’s The Journal of Applied Laboratory Medicine
Association for Diagnostic and Laboratory Medicine (ADLM (formerly AACC))

Molecular diagnostics is a powerful branch of laboratory medicine that examines the fundamental genetic and biochemical components of life to provide invaluable insights into health and disease.

Newswise: Novel Genetic Priority Score Unveiled to Enhance Target Prioritization in Drug Development
2-Jan-2024 1:05 PM EST
Novel Genetic Priority Score Unveiled to Enhance Target Prioritization in Drug Development
Mount Sinai Health System

Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel “genetic priority score” (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score. The findings were described in the January 3 online issue of Nature Genetics [DOI: 10.1038/s41588-023-01609-2]. Studies have shown that drugs have an increased likelihood of success in clinical trials when the genes they target have been demonstrated to have genetic support. The new tool integrates multiple lines of genetic evidence to prioritize these drug targets.

Released: 2-Jan-2024 4:05 PM EST
دراسة تظهر أن الجزيئات المناعية قد يكون لها دورًا رئيسيًا في تطور مرض التصلُّب الجانبي الضموري (ALS)
Mayo Clinic

حدد الباحثون والمتعاونون في مايو كلينك بروتينًا تفرزه الخلايا المناعية والذي قد يقوم بدورٍ رئيسيٍ في ظهور مرضالتصلُّب الجانبي الضموري، المعروف أيضًا باسم مرض لو غيريغ. ووجد الفريق أيضًا أن العلاج التعديلي المناعي الذي يقوم بعملية إِحْصار للبروتين يمكنه استعادة الوظيفة الحركية في النماذج قبل السريرية. وتشير النتائج إلى أن البروتين، المعروف باسم أ5 إنتغرين (الذي يُنطق ألفا 5 إنتغرين)، هو مستهدف علاجي محتمل لعلاج مرض التصلُّب الجانبي الضموري.

Released: 2-Jan-2024 3:05 PM EST
Un estudio muestra que una molécula del sistema inmunitario puede desempeñar un rol clave en la evolución de la ELA
Mayo Clinic

Los investigadores y colaboradores de Mayo Clinic han identificado una proteína expresada en células inmunitarias que podría desempeñar un rol clave en el desarrollo de la esclerosis lateral amiotrófica (ELA), también conocida como enfermedad de Lou Gehrig. El equipo también descubrió que un tratamiento inmunomodulatorio que bloquea la proteína era capaz de restaurar la función motriz en modelos preclínicos. Los hallazgos indican que la proteína, conocida como integrina α5 (pronunciado integrina alfa 5), es un posible blanco terapéutico para la ELA.

Released: 2-Jan-2024 3:05 PM EST
Estudo mostra que molécula imunológica pode desempenhar uma função fundamental na progressão da ELA
Mayo Clinic

Pesquisadores e colaboradores da Mayo Clinic identificaram uma proteína que é expressa por células imunológicas que pode desempenhar uma função importante no desenvolvimento daesclerose lateral amiotrófica (ELA), também conhecida como doença de Lou Gehrig. A equipe também descobriu que um tratamento imunomodulador que bloqueia a proteína conseguiu restaurar a função motora em modelos pré-clínicos. As descobertas sugerem que a proteína, conhecida como integrina α5 (pronunciada como integrina alfa 5), é um possível alvo terapêutico para ELA.

Newswise: Demystifying a Key Receptor in Substance Use and Neuropsychiatric Disorders
Released: 2-Jan-2024 11:05 AM EST
Demystifying a Key Receptor in Substance Use and Neuropsychiatric Disorders
Mount Sinai Health System

Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric disorders. This discovery may pave the way for the development of improved medications targeting the same pathway. Their findings, detailed in the January 2 online issue of Nature Communications https://doi.org/10.1038/s41467-023-44601-4, show that a brain protein known as the TAAR1 receptor, a drug target known to regulate dopamine signaling in key reward pathways in the brain, differs significantly in humans compared to the preclinical rodent models on which drugs are typically tested. The study suggests considering species-specific differences in drug-receptor interactions and further investigation into ways asenapine affects the body, as steps toward potential therapeutic improvements.

Newswise: Johns Hopkins Medicine Lab Awarded $15 Million to Study Targeted Radiation for Treatment-Resistant Cancers
Released: 27-Dec-2023 10:05 AM EST
Johns Hopkins Medicine Lab Awarded $15 Million to Study Targeted Radiation for Treatment-Resistant Cancers
Johns Hopkins Medicine

The Radiopharmaceutical Therapy and Dosimetry Lab at Johns Hopkins Medicine, headed by George Sgouros, Ph.D., has been awarded a $15 million grant, to be dispersed over the next five years, from the National Cancer Institute at the National Institutes of Health.

Newswise: New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation
18-Dec-2023 3:05 PM EST
New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation
Mount Sinai Health System

Patient-specific mutation-engineered mouse reveals how sensory neurons may trigger some allergy conditions but block others, suggesting more precise design of JAK inhibitors is necessary.

Released: 20-Dec-2023 3:05 PM EST
Working with Big Data requires a lot of power! The latest research and features on Supercomputing
Newswise

With the rise in machine learning applications and artificial intelligence, it's no wonder that more and more scientists and researchers are turning to supercomputers. Supercomputers are commonly used for making predictions with advanced modeling and simulations. This can be applied to climate research, weather forecasting, genomic sequencing, space exploration, aviation engineering and more.

       
Newswise: Common drug for cardiac failure jams a debated blood test for Alzheimer’s disease
Released: 19-Dec-2023 12:05 PM EST
Common drug for cardiac failure jams a debated blood test for Alzheimer’s disease
University of Gothenburg

Alzheimer’s disease (AD) is associated with damaging protein aggregates in the brain, with β-amyloid (Aβ) aggregates called plaques being the key pathology. Entresto (sacubitril/valsartan) is a combined neprilysin inhibitor and angiotensin receptor blocker, approved for the treatment of heart failure.

Newswise: Potential of Forsythiae Fructus in Mitigating Chemotherapy-Induced Gastrointestinal Inflammation and Nausea
Released: 19-Dec-2023 7:20 AM EST
Potential of Forsythiae Fructus in Mitigating Chemotherapy-Induced Gastrointestinal Inflammation and Nausea
Chinese Academy of Sciences

The authors of this study verified that Forsythiae Fructus and Forsythrin A and phillyrin has a therapeutic effect on CINV, and it also provides a reference treatment for the management of CINV.

Not for public release

This news release is embargoed until 18-Dec-2023 5:00 PM EST Released to reporters: 12-Dec-2023 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 18-Dec-2023 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 18-Dec-2023 5:00 PM EST Released to reporters: 12-Dec-2023 2:00 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 18-Dec-2023 5:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Dec-2023 10:05 AM EST
Psychedelic psilocybin-assisted therapy reduces depressive symptoms in adults with cancer and depression
Wiley

Results from a phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe, may benefit individuals with cancer and major depression.

Newswise: Nabsolute, a Start-Up from the Faculty of Pharmaceutical Science, Wins National Innovation Award 2023
Released: 18-Dec-2023 8:55 AM EST
Nabsolute, a Start-Up from the Faculty of Pharmaceutical Science, Wins National Innovation Award 2023
Chulalongkorn University

Nabsolute Co., Ltd., a startup from the Faculty of Pharmaceutical Science, Chulalongkorn University, developer of Hy-N, an innovative biopolymer delivery system that improves the efficiency of cosmeceuticals, medicines, and vaccines, received the 2023 National Innovation Award in the economic category as a small and micro-enterprise from the National Innovation Agency (NIA).

Newswise: New method paves the way for new antibiotics
Released: 15-Dec-2023 1:05 PM EST
New method paves the way for new antibiotics
Norwegian University of Science and Technology (NTNU)

Singleton is the lead author of a study that shows how a combination of two new substances effectively kills methicillin-resistant Staphylococcus aureus (MRSA).

Released: 14-Dec-2023 8:55 AM EST
AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China
AbelZeta Pharma, Inc.

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company.

   
5-Dec-2023 2:45 PM EST
Study exposes opportunities for strengthening cancer drugs trials in China
PLOS

More than one-eighth of the randomized trials of cancer drugs seeking regulatory approval in China in recent years used inappropriate controls to test the effectiveness and safety of the drugs, according to a new study published December 12th in the open access journal PLOS Medicine by Professor Xiaodong Guan of Peking University, China, and colleagues.

Released: 12-Dec-2023 1:30 PM EST
Vitamin D crucial for gut health: Deficiency linked to inflammation in IBD patients
Wolters Kluwer Health: Lippincott

Lower levels of vitamin D found in inflammatory bowel disease (IBD) patients are linked to inflammation, potentially playing a role in the disease's development, findings from a cross-sectional observational study published in Medicine® show.

11-Dec-2023 3:30 PM EST
ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
University of Texas MD Anderson Cancer Center

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

Released: 12-Dec-2023 12:05 PM EST
Nearly 40% of Type 2 diabetes patients stop taking their second-line medication
Northwestern University

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin — the go-to primary drug for glucose management — to control their blood sugar levels. But adherence to these second-line drugs can be hit or miss, reports a new Northwestern Medicine study.

Released: 11-Dec-2023 6:05 PM EST
Novel compounds promise success in the fight against tuberculosis and depression
Technische Universität Dresden

Tuberculosis (TB) is a prevalent infectious disease that affects millions of people each year. It was previously the leading cause of death from a single pathogen before the COVID-19 pandemic. Detecting TB early is challenging because the bacterium Mycobacterium tuberculosis (Mtb) can hide in human macrophages, which are part of the immune system

Released: 11-Dec-2023 5:05 PM EST
Nanoparticle-delivered RNA reduces neuroinflammation in lab tests
Picower Institute for Learning and Memory at MIT

Some Covid-19 vaccines safely and effectively used lipid nanoparticles (LNPs) to deliver messenger RNA to cells. A new MIT study shows that different nanoparticles could be used for a potential Alzheimer’s disease (AD) therapy.

Newswise: First observation of structures resulting from 3D domain swapping in antibody light chains
Released: 8-Dec-2023 2:05 PM EST
First observation of structures resulting from 3D domain swapping in antibody light chains
Nara Institute of Science and Technology

Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising candidates for future drug development.

Released: 8-Dec-2023 1:05 PM EST
Study reveals insights into tacking diabetic kidney disease - with a side order of how anti-obesity drugs work
Monash University

Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective. Importantly, the data also reveals how anti-obesity drugs like Ozempic, actually work, which to date have been a mystery.

Released: 8-Dec-2023 8:05 AM EST
MD Anderson and Rigel Pharmaceuticals announce strategic alliance to advance olutasidenib in AML and other cancers
University of Texas MD Anderson Cancer Center

MD Anderson and Rigel Pharmaceuticals announced a multi-year strategic development collaboration to expand the evaluation of olutasidenib in acute myeloid leukemia and other hematologic cancers.

Newswise: New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease
Released: 8-Dec-2023 6:05 AM EST
New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease
Case Western Reserve University

Researchers at Case Western Reserve University and University Hospitals have identified an enzyme that blocks insulin produced in the body—a discovery that could provide a new target to treat diabetes.

Released: 7-Dec-2023 5:05 PM EST
World-first trial offers new hope for type 1 diabetes
ST Vincent's Institute Of Medical Research

Researchers at St Vincent’s Institute of Medical Research (SVI) in Melbourne have shown that a commonly prescribed rheumatoid arthritis drug can suppress the progression of type 1 diabetes.   The world-first human trial, published today in the New England Journal of Medicine and led by SVI’s Professor Thomas Kay, showed that a drug called baricitinib can safely and effectively preserve the body’s own insulin production and suppress the progression of type 1 diabetes in people who initiated treatment within 100 days of diagnosis.

Released: 6-Dec-2023 6:05 PM EST
Zinc shows promise as surprising emerging treatment for vaginal yeast infections
University of Exeter

New research could one day pave the way for the treatment of vaginal yeast infections, by shedding new light on how microbes in the body absorb zinc.

Released: 6-Dec-2023 6:05 PM EST
Stanford Medicine-led study finds way to predict which of our organs will fail first
Stanford Medicine

Like any typical car or house or society, the pace at which parts of our bodies fall apart varies from part to part.

Released: 6-Dec-2023 2:05 PM EST
Could anti-obesity medications affect survival in people with knee or hip osteoarthritis?
Wiley

New research published in Arthritis & Rheumatology suggests that for people overweight or with obesity who also have knee or hip osteoarthritis, a slow-to-moderate—but not fast—rate of weight loss caused by anti-obesity medications may lower their risk of premature death.

Released: 6-Dec-2023 11:05 AM EST
Common dementia drugs not associated with increased risk of falling, but increased chances of fainting
McMaster University

Researchers from McMaster University have found that cholinesterase inhibitors, a type of common medication used to treat dementia, are not associated with an increased risk of falling. However, they found that the medication increased the risk of syncope, or fainting.

Newswise: Study shows how birth control pills affect women’s psychological and biological responses to stress
Released: 6-Dec-2023 12:05 AM EST
Study shows how birth control pills affect women’s psychological and biological responses to stress
University of California, Los Angeles (UCLA), Health Sciences

A new UCLA Health study is shedding light on how using hormonal contraceptive pills may affect women’s responses to stress and their risk for inflammation-related illnesses.

Newswise: Medicare is Overpaying for Generic Drugs
Released: 5-Dec-2023 10:00 AM EST
Medicare is Overpaying for Generic Drugs
University of California San Diego

Researchers from at University of California San Diego, West Health, and the University of Washington have found evidence that the private insurers that sponsor Medicare Part D are artificially inflating the costs of certain generic drugs by overpaying pharmacies.

Newswise: Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program
Released: 5-Dec-2023 4:05 AM EST
Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program
ISPOR—The Professional Society for Health Economics and Outcomes Research

Value in Health announced the publication of 2 new commentaries by leading HEOR experts, both of which raise important questions as the Centers for Medicare & Medicaid Services move forward to implement the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

Newswise: Leukemia cells activate cellular recycling program
Released: 4-Dec-2023 5:05 PM EST
Leukemia cells activate cellular recycling program
Goethe University Frankfurt

In a recent study, scientists led by Professor Stefan Müller from Goethe University’s Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML. The disease mainly occurs in adulthood and often ends up being fatal for older patients.

Released: 4-Dec-2023 3:05 PM EST
Decoding flavonoid metabolism: a closer look at plant-based diets
Osaka Metropolitan University

In a world where plant-based lifestyles are on the rise, the power of foods such as broccoli, celery, and tofu, which are rich in flavonoids, is becoming clearer. Flavonoids are phenolic compounds produced by plants that are essential for plant development and defense and have long been said to have therapeutic and preventive effects against cancer and heart disease.

Newswise: Study: New Biomarker Tool Helps Select Targeted Therapies to Treat Metastatic Breast Cancers
Released: 4-Dec-2023 3:05 PM EST
Study: New Biomarker Tool Helps Select Targeted Therapies to Treat Metastatic Breast Cancers
Yale Cancer Center/Smilow Cancer Hospital

Two antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), were approved by the FDA to treat metastatic breast cancers. ADCs are a type of targeted therapy that release cancer drugs to specific tumor cells. The efficacy of T-DXd and SG depends on target expression and the best method for measuring that expression is still not known.

Released: 4-Dec-2023 2:05 PM EST
Breakthroughs in nanosized contrast agents and drug carriers through self-folding molecules
Tokyo Institute of Technology

Self-folding polymers containing gadolinium forming nanosized complexes could be the key to enhanced magnetic resonance imaging and next-generation drug delivery, as demonstrated by scientists at Tokyo Tech. Thanks to their small size, low toxicity, and good tumor accumulation and penetration, these complexes represent a leap forward in contrast agents for cancer diagnosis, as well as neutron capture radiotherapy.

Newswise: Promising Phase III Results Give Hope to Patients with Myelodysplastic Syndromes
Released: 4-Dec-2023 9:30 AM EST
Promising Phase III Results Give Hope to Patients with Myelodysplastic Syndromes
Yale Cancer Center/Smilow Cancer Hospital

Based on the results from this phase III trial, Yale Cancer Center expert Dr. Amer Zeidan says imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower risk MDS patients.

Newswise: Experimental Drug Combination Shows Promise Against Hard-to-Treat Peripheral Nerve Sheath Tumors
29-Nov-2023 12:00 PM EST
Experimental Drug Combination Shows Promise Against Hard-to-Treat Peripheral Nerve Sheath Tumors
Johns Hopkins Medicine

Dr. Kathryn Lemberg in her lab. Credit: Norm Barker Combining a pair of experimental drugs may help treat malignant peripheral nerve sheath tumors with fewer harmful side effects, according to preliminary animal studies led by investigators at the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery. 

Newswise: ASPET President Namandjé Bumpus to Assume FDA Principal Deputy Commissioner Role
Released: 1-Dec-2023 8:55 AM EST
ASPET President Namandjé Bumpus to Assume FDA Principal Deputy Commissioner Role
Federation of American Societies for Experimental Biology (FASEB)

The American Society for Pharmacology and Experimental Therapeutics President Namandjé Bumpus will take over as the U.S. Food and Drug Administration’s (FDA) Principal Deputy Commissioner early next year.



close
2.19136